关键词:

原发性胶质母细胞瘤, 同步放化疗, IDH1, MGMT, 预后

Abstract:

Objective To explore the expression of IDH1，MGMT，and p53 in primary glioblastoma（pGBM） after postoperative concurrent radiochemotherapy through a retrospective study and analyze its prognosis in order to provide the patients with individualized and precise treatment. Methods The clinical data，IDH1 gene，MGMT promoter methylation，and p53 protein expression of 107 pGBM patients admitted to our hospital and Zhengda First Affiliated Hospital for concurrent radiochemotherapy from January 2014 to June 2018 through the electronic medical record system. Statistical analysis was performed using SPSS 21.0. Results The positive expression rates of IDH1 mutation，mMGMT and p53 protein in the pGBM patients with concurrent radiochemotherapy were 9.34%，31.78%， and 15.89%，respectively. The pGBM patients with age ≤ 55，non⁃functional area，IDH1 mutation and concurrent radiochemotherapy had longer progression ⁃free survival（PFS）and overall survival（OS）（P < 0.05）. Conclusion IDH1，tumor location，and age are independent factors affecting the prognosis of pGBM patients with concurrent radiochemotherapy. IDH1 mutation indicates longer PFS and OS in the patients with concurrent radiochemotherapy， and therefore it is an important molecular marker for predicting the prognosis of patients.

Key words:

primary glioblastoma, concurrent radiochemotherapy, IDH1, MGMT, prognosis